Related Experiment Video
Updated: Jul 14, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Effect of olmesartan on oxidative stress in hemodialysis patients
Daisuke Kadowaki1, Makoto Anraku, Yuka Tasaki
1Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Insights
Olmesartan, an angiotensin II receptor blocker, reduces oxidative stress in hemodialysis patients. This study shows olmesartan decreases oxidized albumin and albumin hydroperoxides, potentially offering benefits beyond blood pressure control.
Area of Science:
- Nephrology
- Cardiovascular Pharmacology
- Oxidative Stress Research
Background:
- Oxidative stress is a concern in hemodialysis (HD) patients.
- The specific impact of olmesartan, an angiotensin II type 1 receptor blocker (ARB), on oxidative stress markers in HD patients requires further investigation.
Purpose of the Study:
- To investigate the in vitro and in vivo effects of olmesartan on oxidative stress in hemodialysis patients.
- To determine if olmesartan reduces oxidized albumin and albumin hydroperoxides.
Main Methods:
- In vitro study: High-performance liquid chromatography (HPLC) and ferrous oxidation xylenol assay to measure oxidized albumin and albumin hydroperoxides with and without olmesartan.
- In vivo study: Six hypertensive HD patients received 40 mg of olmesartan daily, with blood pressure and oxidized to unoxidized albumin ratio monitored over 8 weeks.
Main Results:
- In vitro: Olmesartan significantly decreased oxidized albumin ratios and albumin hydroperoxides in a concentration-dependent manner.
- In vivo: Olmesartan significantly reduced systolic and diastolic blood pressure within 4 weeks, with sustained reduction at 8 weeks.
- In vivo: The ratio of oxidized to unoxidized albumin was markedly decreased after 4 weeks and maintained at 8 weeks.
Conclusions:
- Olmesartan effectively reduces the oxidation of albumin both in vitro and in vivo.
- The antioxidant effects of olmesartan in HD patients may provide benefits independent of its blood pressure-lowering action.
Abstract:
The effect of olmesartan, an inverse angiotensin II type 1 receptor blocker (ARB), on oxidative stress in hemodialysis (HD) patients is not fully understood, and has not been widely investigated in vitro or in vivo. We determined the amount of oxidized albumin and albumin hydroperoxides formed during incubation in the absence and presence of olmesartan by high-performance liquid chromatography (HPLC) and by a ferrous oxidation xylenol assay in an in vitro study. Six hypertensive HD patients were treated with 40 mg of olmesartan once daily, and blood pressure monitoring (BPM) was performed after 0, 4, and 8 weeks of treatment. The ratio of oxidized to unoxidized albumin was also determined. The oxidized albumin ratios and levels of albumin hydroperoxides were significantly decreased in a concentration-dependent manner in the presence of olmesartan, compared with the absence of olmesartan (p<0.05) in in vitro studies. In HD patients, olmesartan also significantly reduced systolic and diastolic blood pressure after 4 weeks, with a further significant decrease after 8 weeks. The ratio of oxidized to unoxidized albumin was markedly decreased after 4 weeks and these lower levels were maintained at 8 weeks. Olmesartan effectively lowered the extent of oxidation of albumin in both in vitro and in vivo studies, and this effect might confer benefits beyond a reduction in blood pressure.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hemodialysis III: Nursing Management
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hemodialysis II: Procedure and Complications
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
